Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Liabilities

Latest as of September 2025: Skr11.18 Million SEK ≈ $1.20 Million USD

Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has total liabilities worth Skr11.18 Million SEK (≈ $1.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Scandinavian ChemoTech AB Series B to assess how effectively this company generates cash.

Scandinavian ChemoTech AB Series B - Total Liabilities Trend (2014–2024)

This chart illustrates how Scandinavian ChemoTech AB Series B's total liabilities have evolved over time, based on quarterly financial data. See Scandinavian ChemoTech AB Series B net assets for net asset value and shareholders' equity analysis.

Scandinavian ChemoTech AB Series B Competitors by Total Liabilities

The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their total liabilities.

Company	Country	Total Liabilities
Intrasense PA:ALINS	France	€14.45 Million
Intelicanna Ltd TA:INTL	Israel	ILA54.71 Billion
Ostin Technology Group Co Ltd NASDAQ:OST	USA	$42.29 Million
Radiant Utama Interinsco Tbk JK:RUIS	Indonesia	Rp710.69 Billion
Globe Kita Terang Tbk PT JK:GLOB	Indonesia	Rp1.10 Trillion
Memphasys Ltd AU:MEM	Australia	AU$6.43 Million
AUX Resources Corporation V:AUX	Canada	CA$649.44K
Burford Capital Limited LSE:BUR	UK	GBX3.50 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Scandinavian ChemoTech AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Scandinavian ChemoTech AB Series B worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.17	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.81	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.64	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scandinavian ChemoTech AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scandinavian ChemoTech AB Series B (2014–2024)

The table below shows the annual total liabilities of Scandinavian ChemoTech AB Series B from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr7.40 Million ≈ $796.36K	+92.81%
2023-12-31	Skr3.84 Million ≈ $413.03K	-50.21%
2022-12-31	Skr7.71 Million ≈ $829.61K	+307.24%
2021-12-31	Skr1.89 Million ≈ $203.72K	-71.98%
2020-12-31	Skr6.75 Million ≈ $726.95K	-12.95%
2019-12-31	Skr7.76 Million ≈ $835.10K	+235.50%
2018-12-31	Skr2.31 Million ≈ $248.92K	-9.52%
2017-12-31	Skr2.56 Million ≈ $275.11K	+13.94%
2016-12-31	Skr2.24 Million ≈ $241.46K	-61.21%
2015-12-31	Skr5.78 Million ≈ $622.47K	+29367.34%
2014-12-31	Skr19.63K ≈ $2.11K	--

About Scandinavian ChemoTech AB Series B

ST:CMOTEC-B Sweden Biotechnology

Market Cap

$10.09 Million

Skr93.78 Million SEK

Market Cap Rank

#26849 Global

#583 in Sweden

Share Price

Skr3.94

Change (1 day)

-1.25%

52-Week Range

Skr1.52 - Skr7.30

All Time High

Skr51358.02